The 5-Ws of immunotherapy in head and neck cancer

被引：13

作者：

Botticelli, Andrea ^{[1
]}

Mezi, Silvia ^{[2
]}

Pomati, Giulia ^{[2
]}

Cerbelli, Bruna ^{[2
]}

Di Rocco, Christiana ^{[3
]}

Amirhassankhani, Sasan ^{[4
]}

Sirgiovanni, Grazia ^{[2
]}

Occhipinti, Mario ^{[2
]}

Napoli, Valerio ^{[2
]}

Emiliani, Alessandra ^{[2
]}

Mazzuca, Federica ^{[1
]}

Tomao, Silverio ^{[2
]}

Nuti, Marianna ^{[5
]}

Marchetti, Paolo ^{[1
]}

机构：

[1] Sapienza Univ Rome, Dept Clin & Mol Med, Viale Regina Elena 326, I-00161 Rome, Italy

[2] Sapienza Univ Rome, Radiol Oncol & Pathol Sci Dept, Policlin Umberto I, Viale Regina Elena 326, I-00161 Rome, Italy

[3] IDI IRCCS, Ist Dermopat Immacolata, Via Monti Creta 104, I-00167 Rome, Italy

[4] Guys & St Thomas NHS Fdn Trust, Westminster Bridge Rd, London SE1 7EH, England

[5] Sapienza Univ Rome, Fac Med & Dent, Dept Expt Med, Viale Regina Elena 326, I-00161 Rome, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 153卷

关键词：

Immunotherapy; Immune checkpoint inhibitors; PD-1/PD-L1; axis; Immunosuppressive microenvironment; Head and neck cancer; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; TUMOR-INFILTRATING LYMPHOCYTES; ANTIGEN-PROCESSING MACHINERY; HPV-ASSOCIATED HEAD; INDUCTION CHEMOTHERAPY; PD-1; BLOCKADE; LUNG-CANCER; T-CELLS; INDOLEAMINE 2,3-DIOXYGENASE;

D O I：

10.1016/j.critrevonc.2020.103041

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The immune checkpoint inhibitors, a class of drugs able to block immune suppressive pathways in order to prime an anticancer immunity, revolutionized standard of care in platinum-refractory recurrent and/or metastatic head and neck carcinoma (R/M HNSCC). The PD-1/PD-L1 axis is involved in the genesis, maintenance and progression of HNSCC and represents the target of checkpoint inhibitors. HNSCC is an immunosuppressive disease with a high inflammatory component in tumor microenvironment. Recent clinical trials showed that only a small subset of patients really benefits from immunotherapy. This review aims to highlight the five W-points of immunotherapy: why immunotherapy is promising in HNSCC, what is currently available in daily clinical practice, when immunotherapy can be integrated into the therapeutic strategy, where it can be useful according to predictive response biomarker, who, among patients, could get the best benefit from immunotherapy and how improve the achieved results.

引用

页数：16

共 130 条

[1] [Anonymous], 2019, J CLIN ONCOL S
[2] Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
Antonia, Scott J.
Balmanoukian, Ani
Brahmer, Julie
Ou, Sai-Hong I.
Hellmann, Matthew D.
Kim, Sang-We
Ahn, Myung-Ju
Kim, Dong-Wan
Gutierrez, Martin
Liu, Stephen V.
Schoffski, Patrick
Jaeger, Dirk
Jamal, Rahima
Jerusalem, Guy
Lutzky, Jose
Nemunaitis, John
Calabro, Luana
Weiss, Jared
Gadgeel, Shirish
Bhosle, Jaishree
Ascierto, Paolo A.
Rebelatto, Marlon C.
Narwal, Rajesh
Liang, Meina
Xiao, Feng
Antal, Joyce
Abdullah, Shaad
Angra, Natasha
Gupta, Ashok K.
Khleif, Samir N.
Segal, Neil H.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1794 - 1806
[3] Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers
Badoual, C
Hans, S
Rodriguez, J
Peyrard, S
Klein, C
Agueznay, NE
Mosseri, V
Laccourreye, O
Bruneval, P
Fridman, WH
Brasnu, DF
Tartour, E
[J]. CLINICAL CANCER RESEARCH, 2006, 12 (02) : 465 - 472
[4] PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
Badoual, Cecile
Hans, Stephane
Merillon, Nathalie
Van Ryswick, Cordelia
Ravel, Patrice
Benhamouda, Nadine
Levionnois, Emeline
Nizard, Mevyn
Si-Mohamed, Ali
Besnier, Nicolas
Gey, Alain
Rotem-Yehudar, Rinat
Pere, Helene
Tran, Thi
Guerin, Coralie L.
Chauvat, Anne
Dransart, Estelle
Alanio, Cecile
Albert, Sebastien
Barry, Beatrix
Sandoval, Federico
Quintin-Colonna, Francoise
Bruneval, Patrick
Fridman, Wolf H.
Lemoine, Francois M.
Oudard, Stephane
Johannes, Ludger
Olive, Daniel
Brasnu, Daniel
Tartour, Eric
[J]. CANCER RESEARCH, 2013, 73 (01) : 128 - 138
[5] Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer
Bauernhofer, T
Kuss, I
Henderson, B
Baum, AS
Whiteside, TL
[J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (01) : 119 - 124
[6] Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Bauml, Joshua
Seiwert, Tanguy Y.
Pfister, David G.
Worden, Francis
Liu, Stephen V.
Gilbert, Jill
Saba, Nabil F.
Weiss, Jared
Wirth, Lori
Sukari, Ammar
Kang, Hyunseok
Gibson, Michael K.
Massarelli, Erminia
Powell, Steven
Meister, Amy
Shu, Xinxin
Cheng, Jonathan D.
Haddad, Robert
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) : 1542 - +
[7] Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma
Baxi, Shrujal S.
Dunn, Lara A.
Burtness, Barbara A.
[J]. ORAL ONCOLOGY, 2016, 62 : 147 - 148
[8] Restoration of HBV-specific CD8+T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation
Bengsch, Bertram
Martin, Bianca
Thimme, Robert
[J]. JOURNAL OF HEPATOLOGY, 2014, 61 (06) : 1212 - 1219
[9] Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
Betof, Allison S.
Nipp, Ryan D.
Giobbie-Hurder, Anita
Johnpulle, Romany A. N.
Rubin, Krista
Rubinstein, Samuel M.
Flaherty, Keith T.
Lawrence, Donald P.
Johnson, Douglas B.
Sullivan, Ryan J.
[J]. ONCOLOGIST, 2017, 22 (08) : 963 - 971
[10] Taxane-Cisplatin-Fluorouracil As Induction Chemotherapy in Locally Advanced Head and Neck Cancers: An Individual Patient Data Meta-Analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group
Blanchard, Pierre
Bourhis, Jean
Lacas, Benjamin
Posner, Marshall R.
Vermorken, Jan B.
Cruz Hernandez, Juan J.
Bourredjem, Abderrahmane
Calais, Gilles
Paccagnella, Adriano
Hitt, Ricardo
Pignon, Jean-Pierre
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) : 2854 - +

← 1 2 3 4 5 6 7 8 9 10 →